3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Spinal Cord Neoplasms
1
Pituitary Neoplasms
1
Parkinson Disease
1
Nervous System Diseases
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Hematologic Diseases
1
Epilepsy
1
Brain Neoplasms
1
Bone Marrow Diseases
1
Interventions
fludarabine
10
ruxolitinib
9
fludarabine phosphate
9
Whole-Body Irradiation
9
Specimen Handling
9
Cyclophosphamide
8
Azacitidine
8
Mycophenolic Acid
7
Cytarabine
7
Busulfan
7
Biopsy
7
Tacrolimus
6
venetoclax
5
Stem Cell Transplantation
5
Sirolimus
5
Peripheral Blood Stem Cell Transplantation
5
Injections
5
Granulocyte Colony-Stimulating Factor
5
Melphalan
4
Cyclosporine
4
CPX-351
4
luspatercept
3
ivosidenib
3
decitabine and cedazuridine drug combination
3
Thiotepa
3
Methotrexate
3
Liposomes
3
Idarubicin
3
Daunorubicin
3
Cyclosporins
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Clinical Laboratory Techniques
×
90 days
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled